- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 12.11.25 | Alkermes races to phase 3 after posting another narcolepsy win | ||
| 12.11.25 | Bayer bails on Vividion tumor drug as part of early-stage cancer clear-out | ||
| 12.11.25 | Metagenomi sheds 25% of workforce, including CEO, to focus on preclinical hemophilia program | ||
| 11.11.25 | With Summit leading the pack in PD-1xVEGF bispecifics, Pfizer lays out its own plan to replace Keytruda | ||
| 11.11.25 | Neuphoria, reeling from phase 3 trial fail, mulls buyout offer from investor | ||
| 11.11.25 | Novo Nordisk shares mixed data behind pivotal heart disease push | ||
| 11.11.25 | Neurocrine's depression drug is latest asset from Takeda pact to flunk a phase 2 trial | ||
| 10.11.25 | Voyager, Transition Bio set sail on neuro research trek in search for small molecule candidates | ||
| 10.11.25 | AI-driven Iambic raises $100M-plus as it looks to advance pipeline, strike more deals | ||
| 10.11.25 | Cogent eyes FDA submission for cancer asset after clearing another phase 3 hurdle | ||
| 10.11.25 | Merck's PCSK9 pill holds 'significant advantage' with injectable-like cholesterol reductions: analysts | ||
| 10.11.25 | AnaptysBio abandons rosnilimab for ulcerative colitis after phase 2 fail | ||
| 10.11.25 | Lyell hands over $70M-plus in cash, equity for 'impressive' phase 1-stage colorectal cancer CAR-T | ||
| 10.11.25 | Roche reports phase 3 multiple sclerosis wins for BTK inhibitor, succeeding where rivals failed | ||
| 10.11.25 | AstraZeneca's $1.3B bet reduces blood pressure by 14 mmHg over 12 weeks in phase 3 win | ||
| 10.11.25 | FDA puts Tenaya heart disease gene therapy clinical trial on hold | ||
| 10.11.25 | Eli Lilly pens $1.2B pact with Sanegene to better target metabolic RNA meds | ||
| 08.11.25 | Pfizer beats out Novo with $10B agreement to buy Metsera | ||
| 07.11.25 | Sana, CAMP4 ditch clinical-stage assets for more promising preclinical candidates | ||
| 07.11.25 | Patient dies after receiving Intellia's CRISPR therapy | ||
| 06.11.25 | FDA reveals second round of 'national priority' voucher winners, including obesity giants Lilly and Novo | ||
| 06.11.25 | Cullinan sidelines pair of oncology assets amid expansion into autoimmune R&D | ||
| 06.11.25 | Axsome adds AstraZeneca epilepsy candidate to pipeline through Avenue subsidiary acquisition | ||
| 06.11.25 | UroGen hands anti-CTLA-4 drug back to Agenus after being unimpressed with phase 1 data | ||
| 06.11.25 | Eli Lilly links amylin agonist to 20% weight loss, sparking charge into phase 3 |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .